Inspiratory Muscle Training May Increase Peak Inspiratory Flow in Chronic Obstructive Pulmonary Disease
- 1 March 2006
- journal article
- research article
- Published by S. Karger AG in Respiration
- Vol. 73 (2), 151-156
- https://doi.org/10.1159/000088095
Abstract
Background: When choosing a specific inhalation device for a chronic obstructive pulmonary disease (COPD) patient, the internal airflow resistance and the ability of the patient to overcome it and to create an optimal inspiratory flow are essential. Objectives: The purpose of the present study was to investigate: (1) the peak inspiratory flow (PIF) that a patient with COPD can generate while breathing through two dry powder inhalers and (2) whether in patients with low PIF specific inspiratory muscle training (SIMT) will increase the PIF and exceed the minimal PIF that is considered necessary to guarantee optimal lung deposition of the drug. Methods: Inspiratory muscle strength and PIFs were measured in 60 patients with COPD. Then 28 patients with severe COPD and low PIF were randomized to receive SIMT or to a control group. Results: With the Turbuhaler, 12 patients (20%) could not generate the optimal flow of 60 l/min. PIF correlated very well with maximal inspiratory mouth pressure (PImax) for the Diskus and the Turbuhaler, as well as for both males and females (p < 0.001). Following the training period, there was a statistically significant increase in the PImax in the training group. This increase was associated with a significant increase in the PIF. All patients overcame the minimal threshold PIF following the training. Conclusions: Some patients with severe COPD are not able to generate adequate flow to secure optimal lung deposition of the inhalation with the Turbuhaler. SIMT improves inspiratory muscle strength as well as PIF. Following 8 weeks of training, the optimal PIF enabling adequate lung deposition of the drug was attained in all the trained patients.Keywords
This publication has 18 references indexed in Scilit:
- Comparable Efficacy and Tolerability of Formoterol (Foradil®) Administered via a Novel Multi-Dose Dry Powder Inhaler (Certihaler™) or the Aerolizer® Dry Powder Inhaler in Patients with Persistent AsthmaRespiration, 2004
- Efficacy, Safety, and Acceptance of Beclomethasone Dipropionate Administered via a New Dry Powder Inhaler or a Standard CFC Metered-Dose Inhaler in Asthma PatientsRespiration, 2003
- Effects of Inhaled Corticosteroids with Different Lung Deposition on Exhaled Hydrogen Peroxide in Stable COPD PatientsRespiration, 2003
- Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialThe Lancet, 2003
- Measurement of peak inhalation rates with an In-Check Meter®to identify an elderly patient's ability to use a Turbuhaler®Respiratory Medicine, 2001
- Eosinophil lysis and plasma extravasationEuropean Respiratory Journal, 1997
- Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers Part 2: Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalersInternational Journal of Pharmaceutics, 1996
- Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers Part 1. Inhalation characteristics, work of breathing and volunteers' preference in dependence of the inhaler resistanceInternational Journal of Pharmaceutics, 1996
- Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task ForceEuropean Respiratory Journal, 1995
- Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjectsEuropean Respiratory Journal, 1994